Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Technology Transfer Opportunities In Brief

This article was originally published in The Gray Sheet

Executive Summary

Midwestern small device firms: U.S. companies with 500 or fewer employees can meet individually with federal program managers and attend seminars about Small Business Innovation Research and Small Business Technology Transfer grants as part of September SWIFT-V tour. Midwestern stops include Louisville (Sept. 9), Memphis (Sept. 13), St. Louis (Sept. 13), Chicago (Sept. 14), Indianapolis (Sept. 15) and Detroit (Sept. 16). An estimated $2 bil. in SBIR/STTR funding is awarded annually, in payments reaching $100,000 for Phase I R&D and $750,000 for Phase II research. More SWIFT-V information is available at 1www.sbiroutreach.com, sponsored by Washington, D.C.-based D.J. & Associates...

You may also be interested in...



Journey East: How Chinese Returnees Build Global-Bound Biopharmas

As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.

US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says

Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.

COVID-19 Vaccines: AstraZeneca’s UK Study Not Good Enough For US FDA Authorization, Slaoui Says

Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel